Current status of the immunogenicity of enzyme replacement therapy in fabry disease

Current status of the immunogenicity of enzyme replacement therapy in fabry disease

Abstract In patients with Fabry disease (FD), treatment with enzyme replacement therapy (ERT), may trigger the formation of anti-drug antibodies (ADAs). The consequences of this immune reaction range from the transient appearance of clinically insignificant ADAs to the generation of neutralizing ant...

Full description

Saved in:
Bibliographic Details
Main Authors: Jorge F. Gómez-Cerezo, Julián Fernández-Martín, Miguel Ángel Barba-Romero, Rosario Sánchez-Martínez, Alvaro Hermida-Ameijeiras, Maria Camprodon-Gómez, Saida Ortolano, Mónica A. Lopez-Rodriguez
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Fabry
Immunogenicity
Antidrug antibodies
Enzyme replacement therapy
Agalsidase
Pegunigalsidase
Online Access:https://doi.org/10.1186/s13023-025-03705-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13023-025-03705-4

Similar Items